




¹⁷⁷Lu-EBRGD

Targeting $\alpha_v\beta_3$ overexpressing tumors


In development for the treatment of Glioblastoma Multiforme (GBM) and Non-Small Cell Lung Cancer (NSCLC)

PET/CT slice of a glioblastoma (GBM) patient




⁶⁴Cu-EBRGD
24 H post injection


1 H




8 H



12 H



24 H



Challenges

- Lack of effective treatment for GBM
- Only limited number of NSCLC patients respond to immunotherapy
- NSCLC incidence 58/100k
- GBM incidence 5/100K

Solution

⁶⁴Cu and ⁶⁸Ga radiolabeled Evans Blue (EB) conjugates prolong circulation half-life and improve tumor targeting in $\alpha_v\beta_3$ -expressing tumors, markedly improved over NOTA- or DOTA-conjugated c(RGDfK) therapeutics.

Technology

Patent pending.

Proof of Concept

Extensive preclinical and Phase I theranostic studies show good safety and efficacy.

Next

- IND in mid 2021
- Phase I trials start in late 2021

MTTI

Molecular Targeting Technologies, Inc. is a privately held biotechnology company focused on the development of novel prolonged targeted radiotherapeutics (PTR) for disease treatment.

Contact: cpak@mtarget.com

More information: www.mtarget.com.